摘要
目的探讨甘氨双唑钠放射增敏联合术前同步放化疗治疗临床Ⅱ、Ⅲ期直肠癌的临床疗效和安全性。方法将49例Ⅱ、Ⅲ期直肠腺癌患者分为甘氨双唑钠组(A组,19例)和未使用甘氨双唑钠组(B组,30例)。甘氨双唑钠使用剂量为800mg·m^(-2),每周一、三、五放疗前1小时使用,放疗处方剂量为46~50 Gy,1.8~2 Gy/次,5次/周,同步予以5-氟尿嘧啶/亚乙酸钙或卡培他滨方案化疗。治疗结束后,观察和比较两组患者的临床疗效和不良反应的发生情况,根据术后病理缓解程度评估其临床疗效。结果两组患者病理完全缓解7例(CR,yp T0N0,14.29%),中间缓解16例(IR,yp T1T2N0,32.65%),缓解不佳26例(PR,yp T3T4或N+,53.06%)。其中,A组CR、IR、PR率分别为10.53%、31.58%、57.89%,B组CR、IR、PR率分别为16.67%、33.00%、50.00%,两组比较差异无统计学意义(P=0.921)。两组患者不良反应发生情况比较无显著性差异(P>0.05)。结论甘氨双唑钠不能提高Ⅱ、Ⅲ期直肠癌的病理缓解程度,因此不建议将其用于直肠癌术前新辅助放化疗的增敏治疗。
Objective To investigate the clinical efficacy and safety of Sodium glycididazole combined with preoperative chemoradiotherapy on rectal cancer at stage Ⅱ/Ⅲ. Methods A total of 49 patients were divided into the Sodium glycididazole group （group A, 19 patients） and the control group without Sodium glycididazole （group B, 30 patients）. The dose of Sodium glycididazole was 800 mg·m^-2, which was used one hour before radiotherapy every Monday, Wednesday and Friday. The prescription dose of radiotherapy was 46-50 Gy, 1.8-2.0 Gy/fraction, 5 times per week. The modality of concurrent chemotherapy was Fluorouracile/Calcium folinate or Capecitabine. After treatment, we observed and compared the clinical efficacy and adverse effects of the two groups. The grades of pathologic response were used to assess the clinical efficacy. Results After treatment, there were 7 cases （14.29%） of complete response （CR, ypTON0）, 16 cases （32.65%） of intermediate response （IR, ypT1T2N0） and 26 cases （53.06%） of poor response （PR, ypT3T4 or N＋）. The rates of patients with CR, IR, and PR were respectively 10.53%, 31.58% and 57.89% in group A but 16.67%, 33.00% and 50.00% in group B. The differences of grades of pathologic response between the two groups were insignificant （P =0.921）. There was also no significant difference in adverse effect between the two groups （P 〉0.05）. Conclusions Sodium glycididazole can not improve the degree of pathologic response of rectal cancer at stage Ⅱ/Ⅲ. We do not recommend Sodium glycididazole as radio sensitizer in combination with preoperative chemoradiotherapy to treat rectal cancer at present.
出处
《肿瘤药学》
CAS
2016年第3期185-188,共4页
Anti-Tumor Pharmacy
基金
湖南省肿瘤医院生物靶向调强放射研究室基金
关键词
直肠癌
甘氨双唑钠
同步放化疗
Rectal cancer
Sodium glycididazole
Concurrent chemoradiotherapy
